How to Reverse Aging: A Deep Dive Into What Science Actually Shows (2026)

Expanded long-form analysis · Based on the YourHealthier article "How to Reverse Aging: What Science Actually Shows (2026)" by Tao Wu, with primary-source expansion of the landmark TRIIM trial (Fahy et al., Aging Cell, 2019).

Main article: https://yourhealthier.com/blogs/blog/reverse-aging

⚡ Quick Answer

No therapy has been proven to reverse aging in humans at scale. But several interventions have reduced biological age as measured by epigenetic clocks in controlled trials. Structured exercise lowered GrimAge by 7.44 months in six months of training (Van Damme / De Meyer et al., GeroScience, 2026). A diet-and-lifestyle protocol reduced Horvath age by 3.23 years in just eight weeks (Fitzgerald et al., Aging, 2021). And the TRIIM trial — recombinant human growth hormone (rhGH) plus DHEA plus metformin for 12 months — reversed GrimAge by approximately 2.5 years in nine middle-aged men, with the effect accelerating in the final quarter of treatment and persisting six months after the drugs were stopped (Fahy et al., Aging Cell, 2019). Among supplements, NMN reliably doubles circulating NAD+ within 14 days. The first human trial of partial epigenetic reprogramming (Life Biosciences ER-100) was cleared by the FDA and dosed its first patient in Q1 2026 (ClinicalTrials.gov NCT07290244). Senolytic drugs that clear "zombie cells" remain in early-phase trials. The most accessible reverse-aging strategy in 2026 still combines structured exercise, sleep optimization, Mediterranean-pattern eating, and evidence-based supplements targeting multiple aging pathways — but the TRIIM data are the strongest published proof that biological age reversal is achievable in living humans.

Key Takeaways

  • "Reversing aging" in 2026 means reducing biological age on validated epigenetic clocks, not reversing chronological time. Multiple interventions have achieved measurable biological age reductions in controlled human studies, though none has demonstrated lifespan extension in humans.
  • Exercise is the most proven reverse-aging intervention. A 2025 review in Aging found that structured training programs (not just casual activity) reduce epigenetic age acceleration. A 2026 GeroScience pilot showed six months of cycling training reduced GrimAge by 7.44 months (p = 0.012), with the reduction correlating with VO₂ max gains (R² = 0.27, p = 0.002).
  • The TRIIM trial (2019) remains the only intervention to show epigenetic age reversal plus immune rejuvenation in a human trial. Participants regenerated thymic tissue (TFFF increase, p = 8.57 × 10⁻¹⁷), improved their lymphocyte-to-monocyte ratio above the cardioprotective threshold of 5, and reversed GrimAge by a mean of 2.5 years. The follow-up TRIIM-X trial is ongoing and Intervene Immune has launched an "Immortal Thymus" lifespan study in mice.
  • NAD+ decline feeds into several of the 12 hallmarks of aging. NMN supplementation doubles circulating NAD+ within 14 days (Christen et al., Nature Metabolism, 2026). Whether NAD+ restoration translates to measurable epigenetic age reversal in humans is being tested in ongoing trials. Importantly, the TRIIM paper itself identified a CD38+ monocyte decline as a likely mechanism linking thymus regeneration to tissue NAD+ recovery — tying the immune and metabolic theories of aging together.
  • Partial epigenetic reprogramming entered human trials for the first time in 2026 (Life Biosciences ER-100, FDA IND cleared for optic neuropathies; first patient dosed Q1 2026). This is the technology with the highest theoretical ceiling for age reversal, but it is years from clinical availability outside the eye indication.
  • The practical reverse-aging protocol in 2026: Layer 1 is exercise (both resistance and cardio), sleep (7–8 hours), and whole-food diet. Layer 2 is NAD+ restoration (NMN 250–500 mg/day), vitamin D3, omega-3, and creatine. Layer 3 is physician-supervised options like rapamycin, metformin, and peptide therapy. A TRIIM-style pharmacological protocol is technically accessible today through specialized longevity physicians, but it is expensive (~$18K per year based on Intervene Immune's TRIIM-X enrollment structure), uncontrolled, and not without risk.

What Does "Reverse Aging" Actually Mean?

Aging is not a single process. It is the simultaneous deterioration of at least 12 interconnected biological systems, identified in the scientific literature as the hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled macroautophagy, chronic inflammation, and dysbiosis (López-Otín et al., 2023).

"Reversing aging" could mean addressing any or all of these. In practice, the field has converged on one primary metric: epigenetic clocks, algorithms that estimate biological age from DNA methylation patterns. The most validated clocks include Steve Horvath's original clock (2013), GrimAge (which predicts mortality risk), PhenoAge (which incorporates clinical biomarkers), and DunedinPACE (which measures the current rate of aging).

When researchers say an intervention "reversed aging," they typically mean it reduced biological age on one of these clocks. That is a meaningful finding, because epigenetic age acceleration predicts all-cause mortality, cardiovascular disease, cancer, and cognitive decline at the population level. But epigenetic clock reductions are a surrogate marker, not proof of lifespan extension. No intervention has been proven to extend human lifespan in a controlled trial.

With that framework in mind, here is what actually works, what is promising, and what is speculation — ranked by the strength of the evidence available in 2026, with a deep dive into the single most important human trial in the field: TRIIM.

What Are the 12 Hallmarks of Aging?

The 12 hallmarks of aging are the cell-level changes scientists use to explain why bodies age: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis (López-Otín et al., 2023). The 2023 update added disabled macroautophagy, chronic inflammation, and dysbiosis to the nine hallmarks proposed in 2013.

Each approach in this guide aims at one or more of them. Senolytics target cellular senescence. Epigenetic reprogramming targets epigenetic alterations. NAD+ precursors such as NMN touch several at once, because NAD+ is needed for DNA repair (PARP enzymes), energy metabolism (mitochondrial oxidative phosphorylation), and the control of cellular senescence (sirtuins) (Covarrubias et al., 2021). The TRIIM protocol is unusual because it appears to act on at least four hallmarks simultaneously: thymic/stem-cell exhaustion, chronic inflammation (CRP and monocyte declines), epigenetic alterations (clock reversal), and deregulated nutrient sensing (metformin and DHEA modulate insulin and IGF-1 signaling).

Can Exercise Reverse Aging?

If there is a single intervention with the strongest evidence for reversing biological aging in humans, it is structured exercise. Not general physical activity like walking the dog or taking the stairs, but planned, repetitive, progressive training programs that increase cardiorespiratory fitness and muscular strength.

A 2025 perspective review published in Aging by Kawamura and colleagues at Tohoku University synthesized evidence from both human and animal studies. The core finding: structured exercise training can induce "epigenomic rejuvenation" in blood and skeletal muscle. One study cited in the review found that sedentary middle-aged women reduced their epigenetic age by two years after just eight weeks of combined aerobic and strength training.

A 2026 study published in GeroScience (Van Damme, De Meyer et al.; cited by 11 within months of publication) tested six months of cycling-based endurance training in 42 adults aged 35–65. Participants improved VO₂ max by 20% (p < 0.001). GrimAge decreased by 7.44 months relative to the expected trajectory (p = 0.012). The GrimAge reduction correlated with VO₂ max improvement (R² = 0.27, p = 0.002) but not with body composition changes alone, suggesting that cardiorespiratory fitness itself is the driver, not just weight loss.

The dose that appears to matter: the Kawamura review found that VO₂ peak and VO₂ at ventilatory threshold were more strongly associated with lower epigenetic age acceleration than grip strength or leg extension power. Higher cardiorespiratory fitness predicted younger biological age. Olympic champions showed lower epigenetic age acceleration than non-champions who trained at similar intensities.

What this means practically: if you do nothing else on this list, exercise. Aim for 150+ minutes per week of moderate cardiovascular training (or 75 minutes vigorous), combined with resistance training 2–3 times per week. Specific protocols that showed epigenetic age reduction in published studies include cycling (the Van Damme / De Meyer GeroScience trial), combined aerobic + resistance circuits (the study showing a 2-year reduction in sedentary women), and walking programs in older adults. VO₂ max improvement appears to be the strongest predictor of epigenetic age reduction, so prioritize progressive cardiovascular challenge over comfortable steady-state. If you currently do not exercise, starting with 30 minutes of brisk walking three times per week and adding resistance training produces meaningful fitness gains within 8–12 weeks. This is not new advice. It is, however, now backed by epigenetic clock data showing measurable biological age reduction in controlled studies.

Can Diet and Lifestyle Reverse Biological Age?

A 2021 pilot RCT by Kara Fitzgerald and colleagues, published in Aging, tested an eight-week diet and lifestyle intervention in 43 healthy adult males aged 50–72. The protocol included a specific diet (high in folate, betaine, and polyphenols, moderate in animal protein), supplementation (probiotics and a phytonutrient powder), exercise guidance (30 minutes daily, 5 days per week), stress management (twice-daily breathing exercises), and sleep optimization (minimum 7 hours).

The treatment group showed a 3.23-year decrease in Horvath-clock biological age compared to controls (p = 0.018). This is one of the largest epigenetic age reductions documented in a controlled human trial from a non-pharmaceutical intervention.

The limitation: this was a small pilot study (n = 43) with only male participants. The specific contributions of each protocol component (diet, exercise, sleep, stress management, supplements) cannot be separated. The result has not yet been replicated in a larger, more diverse population. But as a proof of concept that lifestyle changes can measurably reduce biological age in weeks rather than years, it is significant — and it is one of the only controlled trials in the field, which is more than can be said for many of the pharmaceutical approaches discussed below.

The TRIIM Trial: A Deep Dive Into the Only Published Human Aging-Reversal Study

The original YourHealthier article summarizes TRIIM in roughly 200 words. The full study is dense enough to deserve an entire section, because nearly every mechanistic claim made in the modern reverse-aging field traces back to it. The trial, led by Greg Fahy (Intervene Immune), Steve Horvath (UCLA, inventor of the original epigenetic clock and co-developer of GrimAge), and an interdisciplinary team at Stanford and the University of British Columbia, was published in Aging Cell in September 2019 (Fahy et al., doi: 10.1111/acel.13028; PMCID PMC6826138). It is, by the authors' own description, "the first human clinical trial designed to reverse aspects of human aging."

1. The hypothesis: thymic involution drives immunosenescence, and reversing it might reverse aging

Fahy's starting point was the thymus — the small lymphoid organ behind the sternum that produces new T cells. The thymus is largest in childhood, begins shrinking after puberty, and is largely replaced by fat by age 60. This involution matters: thymic output collapses around age 63, the T-cell receptor (TCR) repertoire contracts, and the resulting immunosenescence is linked to rising cancer incidence, infectious-disease mortality, autoimmunity, atherosclerosis, generalized inflammation, and all-cause mortality. Conversely, centenarians maintain thymic function longer than average.

The TRIIM hypothesis: if you can regrow the thymus in adults, you might rejuvenate the immune system, and the immune rejuvenation might — in turn — produce measurable reductions in biological age. Recombinant human growth hormone (rhGH) had already been shown to have thymotrophic effects in aging rats, dogs, and HIV patients (Kelley et al., 1986; Napolitano et al., 2008). The novelty of TRIIM was in combining rhGH with two other drugs to manage its side effects.

2. The protocol: rhGH + DHEA + metformin, daily for 12 months

Ten healthy men aged 51–65 (across two cohorts) were enrolled. Nine completed the 12-month analysis — one was removed after approximately one month for self-reported bradycardia that predated the trial and a belated disclosure of a strong family history of cancer. The intervention:

  • Recombinant human growth hormone (rhGH) — the active thymotrophic agent. rhGH is a known mitogen that raises IGF-1, which is exactly why the other two drugs were added.
  • Dehydroepiandrosterone (DHEA) — the adrenal androgen that declines sharply with age. DHEA opposes several deleterious effects of normal aging in both men and women and was used here primarily to mitigate the "diabetogenic" effect of GH-induced hyperinsulinemia (Marcus et al., 1990).
  • Metformin — the AMPK-activating, mTOR-inhibiting, calorie-restriction-mimicking diabetes drug. Neither DHEA nor metformin has known thymotrophic activity of its own; both were chosen as insulin/IGF-1 modulators.

This is not a casual supplement stack. rhGH is a prescription injectable with real risks, and the combination protocol was designed specifically to balance thymotrophic benefit against metabolic harm.

3. Thymic regeneration — the primary endpoint

The headline result was visual and quantitative: thymic MRI density improved dramatically. The thymic fat-free fraction (TFFF) — the proportion of functional thymic tissue vs. fat — increased significantly (linear mixed-model p = 8.57 × 10⁻¹⁷, i.e., effectively zero chance of a null result). The improvement was significant in 7 of 9 volunteers. Two volunteers had abnormally low baseline thymic fat (high TFFF at the start) and did not significantly improve — their lack of response was not age-dependent, but baseline-TFFF dependent. The implication: the treatment replaces thymic fat with functional tissue, and men whose thymi were already depleted of fat had nothing left to regenerate.

Sternal bone marrow fat-free fraction (BMFFF) also rose, but to a lesser degree, with similar high statistical significance (linear mixed-model p = 9.5 × 10⁻¹²). The pattern was different from thymus, suggesting that the bone marrow change was a real regenerative response — possibly stimulation of T-cell progenitor production by GH — rather than a generalized body-fat reduction from GH.

4. Immune-cell subset changes — the mechanistic surprise

CyTOF analysis of immune cell populations showed three robust changes:

  • Total and CD38+ monocytes declined. This was the largest immune-cell shift in the entire dataset. Monocyte counts stayed suppressed 6 months after treatment ended (p = 0.012 for CD38+ monocytes; p = 0.022 for total monocytes).
  • The lymphocyte-to-monocyte ratio (LMR) rose above 5. This matters because LMR > 5 is the cardioprotective threshold (Gong et al., 2018). Higher LMRs are associated with better prognosis across at least eight cancer types, atherosclerosis, cardiovascular disease, and stroke. At baseline, the TRIIM cohort averaged below 5; by end of treatment and at 6 months post-treatment, they averaged above 5.
  • PD-1+ CD8 T cells declined. These are "exhausted" T cells (TEX), and PD-1 is the same checkpoint molecule that cancer immunotherapy targets. Reducing PD-1+ CD8 T cells suggests partial restoration of T-cell function.
  • Naïve CD4 and naïve CD8 T cells increased modestly. Increases were smaller than those reported in rhGH-treated HIV patients, but the TRIIM cohort was pre-immunosenescent at baseline and not depleted of naïve cells. Even small increases matter because they push back the age-related TCR-repertoire collapse that occurs in the early 60s.

5. The CD38-NAD+ connection — why this matters beyond the immune system

This is the most underappreciated finding in the paper, and it directly ties the TRIIM results to the NAD+ restoration narrative that dominates the supplement world. CD38 is an NADase ectoenzyme that degrades NMN and is the primary cause of age-related tissue NAD+ depletion in mice (Camacho-Pereira et al., 2016). The vast majority of monocytes are CD38+. If TRIIM reduced CD38+ monocytes, it likely raised tissue NAD+. The authors explicitly note that the decline in CRP combined with reduced monocyte levels "suggests the possibility of an increase in tissue NAD+ levels," which would in turn feed into sirtuin-mediated chromatin remodeling and epigenetic-clock reversal. In other words, the immune and metabolic theories of aging may not be competing — they may be the same theory seen from different angles.

6. Epigenetic clock results — four clocks, all reversed

This is the headline number everyone quotes. The team applied four epigenetic clocks — Horvath, Hannum, PhenoAge, and GrimAge — and all four showed significant regression of epigenetic age. The mean change in epigenetic age minus chronological age (EA−A) after 12 months was approximately 2.5 years, relative to the no-treatment expected trajectory. The within-subject reduction was approximately 1.5 years from baseline.

Two features deserve attention:

  • The reversal accelerated over time. The rate of epigenetic aging reversal ran at −1.6 years of biological age per chronological year from months 0–9, then jumped to −6.5 years per year from months 9–12. Whatever the mechanism is, it has a slow ramp-up. A short course would have produced a much smaller effect.
  • The GrimAge effect persisted. GrimAge specifically showed a 2-year decrease in epigenetic vs. chronological age that was still present six months after treatment discontinuation. The other clocks partially regressed after treatment stopped, but GrimAge — the clock that best predicts actual mortality — did not. The authors describe this as "the first report of an increase, based on an epigenetic age estimator, in predicted human lifespan by means of a currently accessible aging intervention."

7. Safety and side effects

Safety was the trial's central concern, given that rhGH raises IGF-1 (a theoretical cancer-promoting signal). The actual safety data were largely reassuring within this small cohort:

  • PSA and percent-free PSA improved by day 15 and stayed favorable through 12 months. (Two volunteers had a brief 6-month PSA spike that reversed; it was attributed to sexual activity near the testing day.)
  • CRP declined significantly by months 9–12 (counter to the worry that augmenting immune activity might worsen age-related inflammation).
  • IL-6 did not change.
  • Insulin was generally controlled by the DHEA and metformin co-administration; one outlier raised mean insulin at 12 months.
  • Glucose did not change.
  • Estimated glomerular filtration rate (eGFR) improved significantly at months 9–12, with a trend still present at 18 months. This is notable because metformin carries a theoretical lactic-acidosis risk in renal impairment, and eGFR improvement makes that risk profile better, not worse.
  • No changes in serum albumin, lipids, hemoglobin, hematocrit, platelet count, electrolytes, hepatic enzymes, or testosterone.

Side effects were mild and typical of rhGH: arthralgias (2 cases), anxiety (1), carpal tunnel syndrome (1), fluid retention (1), mild gynecomastia (1), and muscle soreness (1). Dose modification was required in only two cases. The volunteer removed after a month was withdrawn for self-reported bradycardia (which predated the trial) and a strong family history of cancer that had not been disclosed at enrollment — an exclusion-criteria issue, not a treatment-caused adverse event.

8. An unexpected finding — FGF-21 elevation

FGF-21 (fibroblast growth factor 21) increased at month 12. The authors suggest this may be a novel mechanism by which thymus regeneration occurs, citing Youm et al. (2016). FGF-21 is also a marker of metabolic stress and is elevated by protein restriction and ketogenic states — so its elevation here may reflect a reorganization of metabolic signaling rather than a simple benefit. This is a thread the field has not yet pulled.

9. The honest limitations

TRIIM was tiny (n = 9 for analysis), uncontrolled (no placebo group), exclusively male, and conducted by an investigator with a direct financial interest in the result (Fahy is the founder of Intervene Immune, the company commercializing the protocol). The authors themselves are explicit: "it will be necessary to verify the present results by replicating them in an appropriately powered follow-up study." The epigenetic clock effect sizes are large partly because the expected trajectory is downward — over 12 months a 55-year-old is supposed to gain a year of biological age, so a 1.5-year reduction is a 2.5-year swing against the counterfactual. This is a legitimate way to present the data, but it is not the same as comparing against a randomized control group.

There is also a deeper mechanistic tension the authors acknowledge: most gerontologists favor reducing GH/IGF-1 signaling, not raising it, because GH/IGF-1-pathway mutations extend lifespan in multiple species. Fahy argues that those studies are confounded by developmental programming that does not necessarily apply to non-mutant adults, and that human longevity is more consistently linked to insulin sensitivity than to IGF-1 levels per se. The argument is plausible but unproven, and it places TRIIM in tension with the broad consensus on GH/IGF-1.

10. TRIIM-X: the follow-up

The follow-up trial, TRIIM-X, is now run by Intervene Immune and is enrolling roughly 85–100 participants aged 51–65, including women and minorities — addressing the two biggest demographic limitations of the original. The trial uses an optimized, adaptive protocol with 5–10 blood draws over a 12-month treatment period. Public discussion (including comments from prospective enrollees) places the cost of participation at approximately $18,000 per person, reflecting the intensive physician-supervised model rather than a typical clinical-trial structure. The original article stated that preliminary TRIIM-X data showed ~20% improvements in physical fitness measures and reductions in body fat, with full results expected in 2026.

Intervene Immune has also begun recruiting for a separate "Immortal Thymus Project" — a 4-year lifespan study in 110 mice testing whether continuous thymus maintenance from early adulthood can dramatically extend healthy lifespan. The project is explicitly modeled on a 1972 Nature finding (Fabris) that thymus transplantation produced a 263% lifespan extension in mice. The Immortal Thymus Project is not a human therapy; it is the foundational research needed to justify a much larger TRIIM-style intervention earlier in life.

11. How to access TRIIM-style treatment today

TRIIM is not a consumer product. rhGH is a Schedule III prescription drug in the United States, and prescribing it for off-label anti-aging purposes is legally and professionally fraught for physicians. A small number of longevity-focused clinics offer TRIIM-like protocols, typically to patients aged 50+ who can afford the cost (in the $15K–$25K per year range when bloodwork and physician oversight are included). The safer interpretation of the TRIIM data for the average person is not "go find a doctor to prescribe you growth hormone" but rather: "this is the proof of principle that biological age can be reversed in humans, and it identifies specific mechanisms — thymic regeneration, CD38+ monocyte reduction, LMR improvement, GrimAge-clock reversal — that you can move in the right direction through other, more accessible interventions." Layer 1 (exercise) and Layer 2 (NAD+ restoration, vitamin D, omega-3) cover the same mechanistic ground at a fraction of the cost and risk.

Does NAD+ Restoration Reverse Aging?

NAD+ (nicotinamide adenine dinucleotide) declines roughly 50% between ages 30 and 70. This decline impairs sirtuin activity (the enzymes that regulate DNA repair and epigenetic stability), reduces mitochondrial energy production, and weakens the cell's ability to respond to stress. That is why NAD+ decline is linked to several of the 12 hallmarks of aging rather than being one itself (Covarrubias et al., 2021). The TRIIM data add a second reason to care: tissue NAD+ depletion appears to be driven by CD38+ monocyte accumulation, and reducing that monocyte population is exactly what TRIIM achieved. The two intervention pathways may converge on the same endpoint.

NMN (nicotinamide mononucleotide) is the direct biochemical precursor to NAD+. A January 2026 trial published in Nature Metabolism (Christen et al., 65 healthy adults) confirmed that both NMN and NR approximately double whole-blood NAD+ concentrations in 14 days at 1,000 mg/day. A 2026 meta-analysis pooling 12 RCTs and 513 participants confirmed reliable NAD+ elevation across studies.

The question that matters for reverse aging: does restoring NAD+ reduce biological age? The evidence is preliminary but directional. NAD+ feeds into sirtuin-mediated chromatin remodeling and DNA methylation maintenance, the exact processes that epigenetic clocks measure. Individual user reports of biological age reduction after NMN supplementation exist, but no controlled trial has yet used epigenetic age as a primary endpoint for NMN. Several such trials are underway with results expected in 2026–2027.

What is established: NMN reliably raises NAD+ (the biochemical signal is confirmed). A 12-week trial (Morifuji et al., 2024) showed improved walking speed and sleep quality in older adults at 250 mg/day. The safety profile is clean across published trials at doses up to 1,250 mg/day. For most people, NMN at 250–500 mg/day is a reasonable protocol targeting NAD+ restoration as one component of a multi-pathway aging strategy. See the YourHealthier best NMN supplements guide for product selection, or the NAD+ supplement guide for how NMN compares to NR and niacin.

How Close Is Epigenetic Reprogramming to Reversing Aging?

Partial epigenetic reprogramming — the transient expression of Yamanaka factors (Oct4, Sox2, Klf4, and sometimes c-Myc) to reset age-associated epigenetic marks while preserving cell identity — is the intervention with the highest theoretical potential for age reversal.

In animal models, cyclic partial reprogramming has extended lifespan, improved muscle regeneration, enhanced pancreatic function, and restored youthful epigenetic profiles in mice. A 2024 study by Rejuvenate Bio (Macip et al.) showed that systemically delivered AAV-OSK gene therapy in 124-week-old mice extended median remaining lifespan by 109% over controls while improving frailty scores.

In 2026, Life Biosciences received FDA IND clearance for ER-100, the first human trial of a reprogramming therapy, targeting optic neuropathies (open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy). The first patient was dosed in Q1 2026 (ClinicalTrials.gov NCT07290244). The therapy uses three Yamanaka factors (OSK, excluding the cancer-associated c-Myc) delivered locally to the eye through a doxycycline-inducible system. If the eye trial succeeds, it opens a regulatory pathway for reprogramming therapies in other tissues.

Altos Labs ($3 billion, backed by Jeff Bezos), Retro Biosciences (backed by Sam Altman), and NewLimit (backed by Brian Armstrong) are all developing related approaches, but none has reached human trials. For consumers in 2026: partial reprogramming is not accessible outside of clinical trials. It represents a future direction, not a current option. The closest interventions that influence epigenetic markers today are exercise, caloric restriction, and NAD+ restoration through NMN supplementation.

Can Senolytics Reverse Aging by Clearing Zombie Cells?

Senescent cells accumulate with age, secreting inflammatory factors (the SASP, senescence-associated secretory phenotype) that damage neighboring healthy cells. Clearing these "zombie cells" with senolytic drugs has extended lifespan and healthspan in mice. The question is whether this translates to humans.

The answer so far: partially. The SToMP-AD and STAMINA trials tested dasatinib plus quercetin (D+Q) in older adults with Alzheimer's disease and mild cognitive impairment. Results showed brain penetrance of dasatinib, reduced inflammatory markers, and correlation between TNF-α reduction and cognitive improvement (MoCA scores). A Phase 2 bone-health trial at Mayo Clinic showed only subtle effects. Unity Biotechnology's senolytic candidate failed two Phase 2 trials.

For consumers: quercetin is available OTC, but quercetin alone is not a senolytic. The D+Q combination requires dasatinib, which is a prescription chemotherapy drug. Fisetin (a quercetin-related flavonoid with senolytic properties in cell studies) is being investigated in human trials. Exercise, particularly high-intensity interval training, has been shown to reduce markers of cellular senescence in human muscle tissue, making it the most accessible senolytic strategy available.

Do Anti-Aging Drugs Like Metformin and Rapamycin Reverse Aging?

Three prescription drugs attract the most attention in the reverse-aging conversation, each targeting different aging mechanisms.

Metformin activates AMPK and inhibits mTOR, mimicking caloric restriction. The TAME trial (Targeting Aging with Metformin) is testing whether it delays age-related diseases in non-diabetic adults. As of 2026, no efficacy results have been published. A 21-year DPP follow-up published in JAMA in 2026 found that lifestyle intervention reduced multimorbidity risk while metformin did not. The MASTERS trial showed metformin blunts muscle gains from resistance training. For metabolically healthy people who exercise, the case for metformin is currently weak — and the TRIIM data do not directly help here, because metformin in TRIIM was a side-effect-mitigator for rhGH, not a stand-alone agent.

Rapamycin inhibits mTOR and is the most reliable lifespan extender across species. The PEARL trial published 48-week results in 2025 showing acceptable safety and improved lean tissue mass and reduced pain in women taking 10 mg/week. The Dog Aging Project is testing rapamycin in companion dogs. Rapamycin requires a prescription and has real side effects (mouth sores, impaired wound healing, potential immune suppression).

GLP-1 agonists (semaglutide, tirzepatide) were developed for diabetes and obesity but show cardiovascular and kidney benefits that may extend beyond weight loss. Whether they slow biological aging independent of metabolic improvement is under investigation.

All three require medical supervision. For OTC alternatives targeting overlapping pathways, berberine activates AMPK (like metformin, without prescription), and NMN supports metabolic function through NAD+ restoration.

What Is David Sinclair's Reverse Aging Thesis?

Harvard geneticist David Sinclair, co-director of the Paul F. Glenn Center for the Biology of Human Aging, has been the most prominent public advocate for the idea that aging is reversible. His Information Theory of Aging posits that aging is driven primarily by the loss of epigenetic information, not by irreversible DNA damage, and that this loss can be corrected.

Sinclair's lab demonstrated in 2020 that expression of Yamanaka factors (OSK) could restore vision in old mice by resetting retinal ganglion cell epigenetics to a youthful state. This work was a key foundation for Life Biosciences' ER-100 human trial (Sinclair co-founded Life Biosciences). His personal supplement protocol (NMN 1g/day + resveratrol 1g/day + metformin 800 mg/day + vitamin D3 + vitamin K2) has been widely discussed but is explicitly a personal choice, not a clinical recommendation.

The honest assessment: Sinclair's research contributions are real and significant. The OSK retinal regeneration work is peer-reviewed and published in Nature. But his public claims about aging reversal sometimes outpace the clinical evidence. His personal supplement protocol has not been tested in a controlled trial. The gap between "aging is theoretically reversible" (which is increasingly supported by science, including by TRIIM) and "you can reverse your aging today with these supplements" (which is not proven) is the space where hype lives. The science is moving in Sinclair's direction, but it hasn't arrived at his destination yet.

How Do You Measure If You Are Reversing Aging?

If you implement reverse-aging interventions, how do you know they are working? The field offers several measurement tools, each with strengths and limitations.

  • Epigenetic clocks (TruDiagnostic, Elysium, GlycanAge): measure biological age from DNA methylation patterns. GrimAge and DunedinPACE are the most validated. Best used as serial measurements over time (every 6–12 months) rather than single snapshots. Cost: $200–500 per test.
  • VO₂ max: the gold standard for cardiorespiratory fitness, which strongly correlates with biological age and all-cause mortality. A VO₂ max in the top quartile for your age is associated with sharply lower death risk. Measurable at clinical exercise labs or estimated through field tests. This is the single most actionable biomarker for reverse aging.
  • Blood biomarkers: fasting glucose, fasting insulin, HbA1c, hsCRP (inflammation), homocysteine, vitamin D, lipid panel. These track metabolic health, which deteriorates with aging. Improvements indicate you are addressing metabolic hallmarks of aging. If you want to mirror TRIIM's measurement approach, add a complete blood count with differential so you can calculate the lymphocyte-to-monocyte ratio — the metric Fahy's team found most responsive.
  • Body composition: lean muscle mass and visceral fat percentage, measured by DEXA scan. Sarcopenia (muscle loss) and visceral fat accumulation are hallmarks of aging. Maintaining or increasing lean mass while reducing visceral fat is a measurable reverse-aging outcome.
  • Grip strength: a validated predictor of all-cause mortality in older adults. Simple, cheap, and reliable. If your grip strength is declining, your aging trajectory is accelerating. If it is improving, you are pushing back.

What Can You Actually Do to Reverse Aging in 2026?

Based on the evidence reviewed above, here is what you can actually implement today, organized by evidence strength and accessibility.

Layer 1: Lifestyle (strongest evidence, lowest cost, no prescription). Exercise 150+ minutes/week cardiovascular + resistance training 2–3x/week. This is the only intervention with controlled human data showing measurable epigenetic age reversal in multiple studies. Sleep 7–8 hours, consistent timing. Mediterranean-pattern diet rich in folate, polyphenols, and fiber. Stress management through any effective modality.

Layer 2: Evidence-based supplements (promising data, OTC, established safety). NMN 250–500 mg/day for NAD+ restoration (proven to double NAD+ in 14 days, clean safety profile). Vitamin D3 2,000–5,000 IU/day (deficiency correlates with accelerated biological aging). Omega-3 2 g EPA+DHA/day (anti-inflammatory, cardiovascular mortality reduction). Creatine 3–5 g/day (muscle and cognitive preservation in older adults). Taurine 1–3 g/day (strong preclinical data from a Science paper, long safety record).

Layer 3: Physician-supervised (real potential, higher risk, requires medical guidance). Rapamycin (low-dose weekly, PEARL trial data shows acceptable safety). Metformin (awaiting TAME results, exercise-blunting is a concern). GLP-1 agonists (for metabolic conditions, with emerging aging data). Anti-aging peptides (thin human evidence, evolving regulatory status).

Layer 4: Experimental (not yet accessible, highest theoretical ceiling). Partial epigenetic reprogramming (first human trial in 2026, ER-100). Senolytic drugs (Phase 1 signals only). Gene therapies targeting aging pathways.

Layer 5: TRIIM-style pharmacological protocol (rhGH + DHEA + metformin, physician-supervised, ~$15K–$25K/year). This is technically accessible through specialized longevity clinics and via the Intervene Immune TRIIM-X trial enrollment pathway. It is the only protocol that has actually demonstrated multi-year GrimAge reversal in published human data. It is also uncontrolled, off-label for the rhGH component, and carries non-trivial metabolic and theoretical cancer risks. For the great majority of readers, Layers 1 and 2 cover the same mechanistic ground — thymic support via immune-system repair, NAD+ restoration, reduced systemic inflammation — at a fraction of the cost and risk.

The most common mistake in the reverse-aging space is jumping to Layers 3, 4, and 5 while Layer 1 is inconsistent. The controlled data showing exercise reduces biological age by months to years is stronger than any pharmaceutical result published to date, including TRIIM. Get Layer 1 right first.

Frequently Asked Questions

Is it really possible to reverse aging?

Partially. Multiple interventions have reduced biological age on validated epigenetic clocks in controlled human studies. Exercise, diet-and-lifestyle protocols, and the TRIIM trial (GH + DHEA + metformin) have all demonstrated measurable epigenetic age reversal. Full reversal of aging (returning an 80-year-old to the biology of a 30-year-old) is not currently achievable and may never be. What is achievable is measurable biological age reduction on validated clocks, improved functional markers (VO₂ max, grip strength, walking speed), and restoration of molecular processes (NAD+ levels, immune cell diversity, DNA methylation patterns) that deteriorate with age.

What is the best supplement to reverse aging?

No supplement has been proven to reverse aging in a controlled human trial using epigenetic age as an endpoint. The supplement with the most relevant human trial data is NMN, which doubles NAD+ (a coenzyme that declines with aging and drives multiple hallmarks of aging) in 14 days. Whether NAD+ restoration translates to measurable epigenetic age reversal is being tested in ongoing trials.

Can exercise reverse aging?

Yes, based on epigenetic clock data. Structured exercise programs (not just casual activity) have reduced biological age by months to years in controlled studies. A 2026 GeroScience study showed 6 months of cycling training reduced GrimAge by 7.44 months. An earlier study found 8 weeks of combined aerobic and strength training reduced epigenetic age by 2 years in sedentary women. VO₂ max is the fitness metric most strongly associated with biological age.

What did David Sinclair do to reverse aging?

David Sinclair's lab demonstrated that three Yamanaka factors (OSK) restored vision in old mice by resetting retinal epigenetics. His personal protocol includes NMN 1g/day, resveratrol 1g/day, metformin 800 mg/day, vitamin D3, and vitamin K2. This is a personal routine, not a tested clinical protocol. The mouse vision research is peer-reviewed (Nature, 2020); the personal supplement stack has not been tested in a controlled trial.

How long does it take to reverse aging?

Epigenetic age reductions have been measured in as little as 8 weeks (Fitzgerald diet-and-lifestyle trial: −3.23 years on Horvath clock). Exercise-induced GrimAge reductions were measured at 6 months. NAD+ elevation from NMN occurs within 14 days, though downstream functional effects may take longer. TRIIM produced a 1.5-year within-subject reduction (2.5-year swing vs. expected trajectory) over 12 months, with the rate of reversal accelerating in the final quarter of treatment and the GrimAge benefit persisting 6 months after the drugs were stopped. The timeline depends on the intervention, the baseline health of the individual, and which aging metric you are tracking.

How much does the TRIIM protocol cost?

TRIIM itself was a research trial and is not sold as a product. The follow-up TRIIM-X trial is operated by Intervene Immune and prospective participants have publicly cited an enrollment cost in the ~$18,000 range for the 12-month program. Off-label TRIIM-style protocols offered by longevity clinics typically run $15,000–$25,000 per year when rhGH, DHEA, metformin, physician oversight, and the required bloodwork are included. Insurance does not cover anti-aging use of rhGH.

When will reverse aging be possible for everyone?

Partial reverse aging is possible right now through exercise, diet, and supplementation. Pharmaceutical reverse-aging protocols (like TRIIM) are available through specialized physicians today, at high cost and off-label. The question is when scalable, high-impact therapies (like epigenetic reprogramming) will become clinically available. The most optimistic estimates place partial reprogramming therapies 5–10 years from widespread availability, and that assumes the ER-100 optic-neuropathy trial succeeds and a regulatory pathway generalizes to other tissues.

Bottom Line: If You Wanted to Act on This Today, What Can We Do?

If you wanted to act on this today, here is the highest-leverage sequence, ranked by what the published evidence actually supports:

  1. Get a baseline. Order a fasting blood panel (glucose, insulin, HbA1c, hsCRP, lipid panel, homocysteine, vitamin D, CMP) and a complete blood count with differential so you can calculate your lymphocyte-to-monocyte ratio — the same metric TRIIM tracked. Optionally add an epigenetic clock test (TruDiagnostic, Elysium, or GlycanAge, ~$200–$500) so you have a biological-age starting point. If you can afford a DEXA scan, get one for lean mass and visceral fat.
  2. Lock in Layer 1. 150+ minutes/week of moderate cardio (or 75 vigorous), resistance training 2–3x/week, sleep 7–8 hours on a consistent schedule, and a Mediterranean-pattern diet. This is the only intervention with multiple controlled human trials showing measurable epigenetic age reversal. It is also the only Layer that improves the lymphocyte-to-monocyte ratio at near-zero cost.
  3. Add Layer 2 supplements. NMN 250–500 mg/day (the cleanest NAD+ restoration data, doubles NAD+ in 14 days), vitamin D3 2,000–5,000 IU/day to maintain 25(OH)D > 40 ng/mL, omega-3 2 g EPA+DHA/day, creatine 3–5 g/day, and optionally taurine 1–3 g/day. Total cost: roughly $30–$60/month.
  4. Re-test in 6–12 months. Re-run the same blood panel and the same epigenetic clock. Compare serially, not against population norms. If your GrimAge or DunedinPACE has dropped, you have direct evidence your intervention is working. If your hsCRP, fasting insulin, and LMR have improved, you have indirect evidence the underlying biology is moving in the right direction.
  5. Consider Layer 3 only if Layers 1 and 2 are dialed in. Rapamycin (low-dose weekly) and metformin require a physician and ongoing monitoring. GLP-1 agonists are appropriate if you have metabolic indications. Skip the peptide-of-the-month.
  6. Do not pursue a TRIIM-style rhGH protocol without a clear medical indication and an experienced physician. The data are real but the trial was n = 9, uncontrolled, and run by the company selling the protocol. The same biological pathways — immune-system repair, NAD+ restoration, inflammation reduction — can be moved substantially with Layers 1 and 2 at a fraction of the cost and risk.
  7. Track the reprogramming field but do not wait for it. ER-100 dosed its first patient in Q1 2026 for optic neuropathies. Even in the best case, partial reprogramming will not be a general-purpose therapy for at least 5–10 years. By the time it is available, you will want to be starting from the healthiest possible baseline.

The single most important sentence in this entire field: the controlled data showing that exercise reduces biological age by months to years is stronger than any pharmaceutical result published to date, including TRIIM. Start there.

Main article and full original analysis: How to Reverse Aging: What Science Actually Shows (2026) on YourHealthier.

Sources

  1. Fahy GM, Brooke RT, Watson JP, Good Z, Vasanawala SS, Maecker H, Leipold MD, Lin DTS, Kobor MS, Horvath S. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019 Sep;18(6):e13028. doi:10.1111/acel.13028. PMCID: PMC6826138.
  2. Van Damme M, De Meyer T, et al. Epigenetic age deceleration reflects exercise-induced cardiorespiratory fitness improvements. GeroScience. 2026. (Cited by 11; GrimAge reduction of 7.44 months; R² = 0.27, p = 0.002 for VO₂ max correlation.) Biblio UGent record.
  3. Fitzgerald KN, Campbell T, Makovetsky K, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging (Albany NY). 2021;13(7):9419–9432. doi:10.18632/aging.202913.
  4. Christen L, et al. Comparative NAD+ elevation by NMN and NR. Nature Metabolism. January 2026. (65 healthy adults; ~2× whole-blood NAD+ in 14 days at 1,000 mg/day.)
  5. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243–278. doi:10.1016/j.cell.2022.11.001.
  6. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular responses during aging. Nature Reviews Molecular Cell Biology. 2021;22(2):119–141. doi:10.1038/s41580-020-00313-x.
  7. Life Biosciences. Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies. Press release.
  8. Life Biosciences. Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies. ClinicalTrials.gov NCT07290244.
  9. Intervene Immune. TRIIM-X Clinical Trial and Immune Monitoring Program. https://interveneimmune.com/programs.
  10. Camacho-Pereira J, Tarragó MG, Chini EN, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction that Causes Sarcopenia. Cell Metabolism. 2016;24(6):825–836. doi:10.1016/j.cmet.2016.11.013. (Foundational CD38-NAD+ decline work cited by TRIIM authors.)
  11. Kawamura T, et al. Exercise-induced epigenomic rejuvenation. Aging (Albany NY). 2025. (Perspective review, Tohoku University.)
  12. Morifuji M, et al. Effect of NMN on walking speed and sleep quality in older adults. 2024. (12-week trial at 250 mg/day.)
  13. Rejuvenate Bio / Macip et al. AAV-OSK gene therapy extends lifespan in aged mice. 2024. (124-week-old mice; +109% median remaining lifespan.)
  14. Lu AT, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019. (GrimAge clock paper, co-developed by Horvath.)
  15. YourHealthier. How to Reverse Aging: What Science Actually Shows (2026). https://yourhealthier.com/blogs/blog/reverse-aging. Accessed November 2026.

This article is an expanded analytical long-form based on the YourHealthier blog post linked above and on the primary TRIIM publication. It is for informational purposes only and does not constitute medical advice. rhGH is a Schedule III prescription substance in the United States; prescribing it off-label for anti-aging purposes carries legal, professional, and medical risk. Any pharmacological intervention discussed here should be pursued only under the supervision of a qualified physician.

  

📝 📜 ⏱️ ⬆️